Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SELLAS Life Sciences GroupSLS +12.35%25 Equity-to-Asset is 0.94 as of Mar. 2026, which is 129% above its 10-year median of 0.41. GuruFocus rates SLS with a GF Score™ of 25/100. Among 1,416 Biotechnology companies, SELLAS Life Sciences Group ranks better than 91.74% on this metric.
The historical rank and industry rank for SELLAS Life Sciences Group's Equity-to-Asset or its related term are showing as below:
SLS'
s Equity-to-Asset Range Over the Past 10 Years
Min: -1.28 Med: 0.41 Max: 0.94
Current: 0.94
During the past 13 years, the highest Equity to Asset Ratio of SELLAS Life Sciences Group was 0.94. The lowest was -1.28. And the median was 0.41.
SLS's Equity-to-Asset is ranked better than 91.74% of 1416
companies
in the Biotechnology industry
Industry Median: 0.68
vs SLS: 0.94
SELLAS Life Sciences Group (NAS:SLS) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
SELLAS Life Sciences Group Equity-to-Asset Related Terms
SELLAS Life Sciences Group Equity-to-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SLS vs MBX, BHVN, PHVS: Equity-to-Asset Comparison
For the Biotechnology subindustry, SELLAS Life Sciences Group's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SELLAS Life Sciences Group Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, SELLAS Life Sciences Group's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where SELLAS Life Sciences Group's Equity-to-Asset falls into.
SELLAS Life Sciences Group Equity-to-Asset Calculation
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
SELLAS Life Sciences Group's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SELLAS Life Sciences Group (SLS) has a Equity-to-Asset of 0.94 as of Mar. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on SELLAS Life Sciences Group and its competitors. This is 129% above median its historical median of 0.41. According to the industry distribution chart, SELLAS Life Sciences Group ranks #117 out of 1416 companies in the Biotechnology industry, placing it in the top 8.3%.
Is SELLAS Life Sciences Group's Equity-to-Asset too high?
SELLAS Life Sciences Group's current Equity-to-Asset of 0.94 is 129% above median its 10-year median of 0.41. The Biotechnology industry median Equity-to-Asset is 0.68. SELLAS Life Sciences Group's value of 0.94 is 38.2% above this industry median. Based on the distribution chart, SELLAS Life Sciences Group ranks #117 out of 1416 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, SELLAS Life Sciences Group has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does SELLAS Life Sciences Group's Equity-to-Asset compare to MBX and BHVN?
According to the Biotechnology industry distribution chart, SELLAS Life Sciences Group ranks #117 out of 1416 companies for Equity-to-Asset. This places SELLAS Life Sciences Group in the top 8% of its industry — outperforming the majority of peers. The industry median Equity-to-Asset is 0.68. SELLAS Life Sciences Group's value of 0.94 is 38.2% above this benchmark. While the company's 10-year median is 0.41 vs. the industry median of 0.68, SELLAS Life Sciences Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,416 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. SELLAS Life Sciences Group's current Equity-to-Asset of 0.94 is 38.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on SELLAS Life Sciences Group and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SELLAS Life Sciences Group's current Equity-to-Asset is 0.94, which is 129% above median its own 10-year median of 0.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SELLAS Life Sciences Group stock overvalued right now?
SELLAS Life Sciences Group (SLS) has a current Equity-to-Asset of 0.94. The current Equity-to-Asset is 0.94, which is 129% above median its 10-year median of 0.41 and 38.2% above the Biotechnology industry median of 0.68. SELLAS Life Sciences Group's overall GF Score™ is 25/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For SELLAS Life Sciences Group (SLS), the current Equity-to-Asset is 0.94 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
25GF Score
Get the complete analysis for SLS
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SLS has been successfully added to your 
